SOX12: A Non-Code RNA Drug Target and Biomarker (G6666)

Target Name: SOX12

NCBI ID: G6666

SOX12

SOX12: A Non-Code RNA Drug Target and Biomarker

SOX12 (SRY-box transcription factor 12) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. SOX12 plays a crucial role in the regulation of gene expression and has been associated with various cellular processes, including cell growth, differentiation, and inflammation.

The SOX12 gene is located on chromosome 11p and encodes a protein that contains a domain similar to that of transcription factors, known as a nucleotide-binding oligomerization domain (NBD). NBD is a common structural feature in transcription factors that allows them to interact with specific DNA sequences and regulate gene expression.

Studies have shown that SOX12 is involved in the regulation of gene expression in various organisms, including humans. For example, SOX12 has been shown to play a role in the regulation of stem cell proliferation and differentiation. In addition, SOX12 has been linked to the development and progression of various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition to its potential therapeutic applications, SOX12 also has potential as a biomarker for certain diseases. For example, SOX12 has been shown to be elevated in the brains of individuals with Alzheimer's disease, which suggests that it may be a useful biomarker for this disease. Additionally, SOX12 has been shown to be elevated in the blood of individuals with Parkinson's disease, which could be used as a biomarker for this disease as well.

The SOX12 gene has also been shown to be regulated by various factors, including DNA methylation and histone modifications. For example, studies have shown that SOX12 is subject to DNA methylation, which can alter its expression levels and play a role in the development of certain diseases.

In addition, SOX12 has also been shown to be regulated by histone modifications, which are chemical modifications to the histones that make up the nucleosome. These modifications can alter the structure and function of the histones, which can in turn affect the expression of genes.

Given the potential role of SOX12 in the regulation of gene expression and the association with various diseases, it is an attractive target for drug development. Researchers are currently working to identify small molecules that can specifically modulate SOX12 function and develop these compounds as potential therapeutic agents.

In conclusion, SOX12 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. Its function in the regulation of gene expression and its association with various diseases make it an attractive target for drug development. Further research is needed to fully understand the role of SOX12 in disease and to develop effective therapeutic agents.

Protein Name: SRY-box Transcription Factor 12

Functions: Transcription factor that binds to DNA at the consensus sequence 5'-ACCAAAG-3' (By similarity). Acts as a transcriptional activator (By similarity). Binds cooperatively with POU3F2/BRN2 or POU3F1/OCT6 to gene promoters, which enhances transcriptional activation (By similarity). Involved in the differentiation of naive CD4-positive T-cells into peripherally induced regulatory T (pT reg) cells under inflammatory conditions (By similarity). Binds to the promoter region of the FOXP3 gene and promotes its transcription, and might thereby contribute to pT reg cell differentiation in the spleen and lymph nodes during inflammation (By similarity). Plays a redundant role with SOX4 and SOX11 in cell survival of developing tissues such as the neural tube, branchial arches and somites, thereby contributing to organogenesis (By similarity)

The "SOX12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SOX12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets